After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex ...
Two biotechnology startups on Friday revealed plans to launch initial public offerings, extending a step-up in IPO activity among privately held drug companies. Sionna Therapeutics is working on ...
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results